Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Longitudinal Cohort of Cerebral Small Vessel Disease in Ruijin Hospital

21. juli 2026 opdateret af: Ruijin Hospital

The goal of this observational study is to learn about neuroimage and biomarkers in the cerebral small vessel disease. The main questions it aims to answer are:

  • How does neurovascular coupling change during the progression of CSVD?
  • How is the pattern/mapping of alterations in CSVD biomarkers? Participants will be observed and visit the research center annually to perform multi-modal MRI, PET, neuropsychological tests, and blood tests.

Studieoversigt

Status

Ikke rekrutterer endnu

Detaljeret beskrivelse

This observational study recruits participants with cerebral small vessel disease (CSVD) from hospitals and community-based populations. Healthy volunteers will also be recruited as controls. Longitudinal follow-up of these participants will help clarify the significance of neuroimaging and biological biomarkers during the development and progression of CSVD.

The investigators aim to establish a longitudinal cohort covering the spectrum of CSVD and identify key biomarkers associated with disease progression and cognitive decline. All participants will undergo multimodal MRI, PET imaging (optional) with different tracers, and blood biomarker assessments. Using multimodal MRI, the investigators will investigate alterations in neurovascular coupling and their role in the pathophysiology of CSVD. In addition, PET imaging (optional) and blood biomarkers will be used to characterize the spatial and temporal patterns of disease-related biomarker changes. Furthermore, additional neuroimaging and digital biomarkers will be evaluated within the cohort to improve disease characterization and prognostic prediction.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

400

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200025
        • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
        • Kontakt:
        • Ledende efterforsker:
          • Jingwen Jiang, Dr.
        • Underforsker:
          • Binyin Li, Dr.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ja

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

The population consists of vascular dementia, vascular mild cognitive impairment, and cognitively normal participants.

Beskrivelse

Inclusion Criteria:

  1. Age ≥18 years.
  2. Evidence of cerebral small vessel disease (CSVD) on brain MRI, meeting at least one of the following imaging criteria:

    • White matter hyperintensities (WMH) with a total Fazekas score ≥2;
    • Fazekas score =1 with at least two vascular risk factors (hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoking, or a history of vascular events other than stroke);
    • Fazekas score =1 accompanied by the presence of lacunes;
    • Imaging evidence of a recent subcortical lacunar infarction.
  3. Independent in activities of daily living (modified Rankin Scale [mRS] ≤2).
  4. Able and willing to provide written informed consent.

Exclusion Criteria:

  1. Acute ischemic stroke with a diffusion-weighted imaging (DWI) lesion >20 mm in diameter.
  2. Acute intracerebral hemorrhage.
  3. Acute subarachnoid hemorrhage, a history of aneurysmal subarachnoid hemorrhage or cerebrovascular malformation, or the presence of an untreated intracranial aneurysm >3 mm in diameter.
  4. Previously diagnosed neurodegenerative disorders, such as Alzheimer's disease (AD) or Parkinson's disease (PD).
  5. Definite non-vascular white matter diseases, including multiple sclerosis, adult-onset leukodystrophy, metabolic encephalopathy, or other non-vascular white matter disorders.
  6. Major psychiatric disorders diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
  7. Contraindications to MRI (e.g., severe claustrophobia or MRI-incompatible implants).
  8. Severe systemic diseases (e.g., active malignancy) with an expected life expectancy of less than 5 years.
  9. Inability to complete scheduled follow-up because of geographic, logistical, or other reasons.
  10. Concurrent participation in another interventional clinical trial.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Cognitively Normal
Participants do not have cognitive impairment.
Cerebral small vessel disease without dementia
Participants have vascular cognitive impairment, but no cognitive impairment
Vascular Dementia (VaD)
Participants have vascular cognitive impairment or difficulty in daily activity.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Global cognitive ability
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Mini-mental state examination
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Executive function
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Clock drawing test
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Visual memory
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Rey-Osterich complex figure test
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Short-term memory
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Auditory verbal learning test
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Executive memory
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Symbol-digit test
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Spatial executive function
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Trail making test
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Naming ability
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Boston naming test
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Language ability
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Language fluency test
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Sleep quality
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Sleep disorder
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Movement ability
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Part III of the Unified Parkinson's Disease Rating Scale
baseline, 1 year, 2-year, 3-year, 5-year,10-year

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Brain volume
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Annual changes of volumes of brain
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Connectivity integrity of the neural circuit
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Annual changes of hippocampus related neural connectivity
baseline, 1 year, 2-year, 3-year, 5-year,10-year
Volume of white matter lesions
Tidsramme: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Structural and functional MRI measures, including arterial spin labeling (ASL), diffusion MRI (dMRI), susceptibility-weighted imaging (SWI) and fluid-attenuated inversion recovery (FLAIR).
baseline, 1 year, 2-year, 3-year, 5-year,10-year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

8. juli 2026

Primær færdiggørelse (Anslået)

30. september 2028

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

10. juli 2026

Først indsendt, der opfyldte QC-kriterier

21. juli 2026

Først opslået (Faktiske)

24. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. juli 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

There is not yet a plan to make IPD available to other researchers

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner